Table 4.

Additional data.

VariablesPlacebo-4mg (6 studies, to Week 24)2mg-4mg-extended, 4 Studies
PlaceboBaricitinib 4 mgBaricitinib 2 mgBaricitinib 4 mgAll-bari-RA
Temporary interruption because of AE ≥ 0.2 EAIR for 4 mg–treated patients in placebo-4 mg, n (EAIR)
Skin and subcutaneous tissue disorders2 (0.5)6 (1.5)2 (0.4)5 (0.8)26 (0.4)
Respiratory thoracic and mediastinal disorders2 (0.5)5 (1.2)6 (1.1)6 (1.0)49 (0.7)
Surgical and medical procedures2 (0.5)4 (1.0)4 (0.7)8 (1.3)65 (1.0)
  • AE: adverse events; EAIR: exposure-adjusted incidence rates; bari: baricitinib; RA: rheumatoid arthritis.